Severe cutaneous adverse reaction to drug excipient following brand-to-generic switch of levetiracetam. Lim JA, Jamil A, Ramli NA, Johar FM, et al. Am J Health Syst Pharm 2024;81:e69-e72.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lim JA, Jamil A, Ramli NA, Johar FM, et al. Severe cutaneous adverse reaction to drug excipient following brand-to-generic switch of levetiracetam. Am J Health Syst Pharm 2024;81:e69-e72.
PMID: 37864830